Biocroí, a Dublin, UK-based developer of multi-well microplates for use in the screening of cells in modern drug discovery and advanced research, has raised €880k in funding.
The round was led by Kernel Capital through the Bank of Ireland MedTech Accelerator Fund, which invested €500k, with participation from Enterprise Ireland and private investors, which provided the remainder of the funds.
Founded in 2009 as a spin-out from Trinity College and led by CEO Peadar MacGabhann, Biocroí designs and develops a range of Advanced Microplates designed to solve the problems that have irritated plate users for many years.
The Biocroí Advanced Microplate products use gel-based buffering systems surrounding the wells with a substance which leads to better control of the microplate environment, which in turn improves quality, accuracy and better uniformity of results – resulting in less assay repeats & a significant reduction in the cost of studies.
Advanced Microplates targets pharmaceutical industry R&D laboratories, research institutes and high throughput clinical testing laboratories.